The latest update is out from Inventiva ( (IVA) ).
Inventiva announced the completion of patient enrollment in its Phase 3 NATiV3 clinical trial for lanifibranor, a potential treatment for MASH. The trial exceeded its target enrollment with 1009 patients in the main cohort and 410 in the exploratory cohort. This milestone supports the conditions for a structured financing tranche and positions lanifibranor as a promising candidate for regulatory approval, with topline results expected in the second half of 2026.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is publicly listed on Euronext Paris and the Nasdaq Global Market, and it operates a research and development facility with a scientific team of approximately 90 people.
YTD Price Performance: 37.38%
Average Trading Volume: 9,191
Technical Sentiment Signal: Hold
Current Market Cap: $281.6M
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.